[Treatment of arthrosis with a new non-steroid anti-rheumatic agent (Voltaren). A double blind comparison with indomethacin].

The new antirheumatic agent diclofenac sodium (Voltaren) has been compared with indometacin with respect to tolerance and effect on osteoarthritic symptoms. In a double blind trial two groups of 30 arthritic patients each received Voltaren and indometacin respectively for 12 weeks. The initial dose for both drugs was 75 mg per day. Where the effect was inadequate the dose could be raised to 125 mg daily. The outcome revealed no significant differences of the effect and tolerance between the two drugs. An earlier onset of effect, however, was observed in the Voltaren group.